Although the importance of multidisciplinary care teams is known, unfortunately, cross-specialty knowledge is not always solicited or recommended Read more
The IASLC has established authority as the only global multidisciplinary organization dedicated to overcoming the four major thoracic malignancies- esophageal cancer, lung cancer, mesothelioma, and thymic malignancies. As we enter […] Read more
Now that the positive impact of lung cancer screening on mortality and morbidity is irrefutable, there is an obvious need to find new ways to overcome consistent challenges with implementation […] Read more
Christian Rolfo, MD, PhD, will take the reins as associate director for clinical research in the Center for Thoracic Oncology/Tisch Cancer Institute, Mount Sinai, New York. Previously, Dr. Rolfo served […] Read more
The PARP inhibitor olaparib did not improve PFS or OS compared with placebo when used as a maintenance therapy for patients with platinum-sensitive NSCLC, according to results of the phase […] Read more
A higher tumor mutational burden (TMB) was associated with improved PFS and overall response rate for patients with advanced NSCLC treated with nivolumab plus ipilimumab plus chemotherapy compared with chemotherapy […] Read more
The real-world assessment of durvalumab in patients with unresectable stage III NSCLC in the PACIFIC-R trial has highlighted important differences between this population and that of the original randomized […] Read more
The Role of PORT in Patients With Completely Resected Stage III-N2 NSCLC: A Pro/Con – The Con Side
+more
The controversy about the role of post-operative radiation therapy (PORT) in patients with a completely resected stage III-N2 NSCLC may soon be settled with the forthcoming publication of the results of the randomized LungART trial. Study findings were presented at the 2020 European Society for Medical Oncology Annual Meeti... Read more
The controversy about the role of post-operative radiation therapy (PORT) in patients with a completely resected stage III-N2 NSCLC may soon be settled with the forthcoming publication of the results of the randomized LungART trial. Study findings were presented at the 2020 European Society for Medical Oncology Annual Meeti... Read more
It has been documented and accepted that lung cancer screening saves lives by detecting disease in high-risk individuals at earlier stages, making the disease more treatable and leading to improved […] Read more